Literature DB >> 21965650

Predictors of chronic kidney disease in Korean patients with lupus nephritis.

Su-Jin Moon1, Seung-Ki Kwok, Ji Hyeon Ju, Kyung-Su Park, Sung-Hwan Park, Chul-Soo Cho, Ho-Youn Kim.   

Abstract

OBJECTIVE: Since chronic kidney disease (CKD) is closely associated with cardiovascular disease and mortality as well as endstage renal disease, prediction of progressive CKD is a clinically important issue. We investigated the independent risk factors for the development of CKD in patients with lupus nephritis (LN).
METHODS: The cohort included 322 Korean patients diagnosed with LN between 1985 and 2010. We retrospectively analyzed the clinical and laboratory indices, treatment response, the final renal function, and the biopsy findings. The timing and cumulative risk of developing CKD were identified by Kaplan-Meier methods. The independent risk factors for developing CKD were examined by univariate and multivariate Cox proportional hazards regression analyses.
RESULTS: The median followup time after the diagnosis of LN was 84 months. CKD occurs in 22% of the patients within 10 years after the diagnosis of LN. The probability of developing CKD was significantly associated with the onset time of LN (delayed-onset LN vs initial-onset LN; HR 2.904, p = 0.003), deteriorated renal function [an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m(2) body surface area] at the onset of LN (HR 7.458, p < 0.001), relapse of LN after achieving remission (HR 2.806, p = 0.029), and resistance to induction therapy (HR 8.120, p < 0.001).
CONCLUSION: Our results demonstrate that delayed-onset LN, a decreased eGFR at the time of LN onset, and the failure to achieve a sustained remission are predictors for the development of CKD in Korean patients with LN.

Entities:  

Mesh:

Year:  2011        PMID: 21965650     DOI: 10.3899/jrheum.110363

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

1.  Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis.

Authors:  Luis Fernando Pinto-Peñaranda; Vladimir Duque-Caballero; Javier Darío Márquez-Hernández; Carolina Muñoz-Grajales; Carlos Jaime Velásquez-Franco
Journal:  Clin Rheumatol       Date:  2015-01-17       Impact factor: 2.980

Review 2.  Lupus Nephritis: Improving Treatment Options.

Authors:  Myrto Kostopoulou; Sofia Pitsigavdaki; George Bertsias
Journal:  Drugs       Date:  2022-04-29       Impact factor: 9.546

3.  Chronic kidney disease in Korean patients with lupus nephritis: over a 35-year period at a single center.

Authors:  Howook Jeon; Jennifer Lee; Ji Hyeon Ju; Wan-Uk Kim; Sung-Hwan Park; Su-Jin Moon; Seung-Ki Kwok
Journal:  Clin Rheumatol       Date:  2022-02-18       Impact factor: 2.980

4.  Human Epididymis Protein 4: A Novel Biomarker for Lupus Nephritis and Chronic Kidney Disease in Systemic Lupus Erythematosus.

Authors:  Zaixing Yang; Zhiyu Zhang; Baodong Qin; Ping Wu; Renqian Zhong; Lin Zhou; Yan Liang
Journal:  J Clin Lab Anal       Date:  2016-04-13       Impact factor: 2.352

5.  Comparison of renal remission and relapse-free rate in initial- and delayed-onset lupus nephritis.

Authors:  Eiji Suzuki; Makiko Yashiro-Furuya; Jumpei Temmoku; Yuya Fujita; Naoki Matsuoka; Momoko Hazama; Tomoyuki Asano; Shuzo Sato; Hiroko Kobayashi; Hiroshi Watanabe; Takashi Kanno; Kiyoshi Migita
Journal:  Int J Rheum Dis       Date:  2021-10-11       Impact factor: 2.558

6.  Glomerular diseases outcome at one year in a tertiary care centre.

Authors:  Huma Mamun Mahmud; Darshan Kumar; Humera Irum; Syed Farman Ali
Journal:  Pak J Med Sci       Date:  2015 Mar-Apr       Impact factor: 1.088

7.  Relationship between hypoalbuminemia, hyperlipidemia and renal severity in patients with lupus nephritis: a prospective study.

Authors:  Manshu Sui; Xibei Jia; Chengyuan Yu; Xiaofang Guo; Xiaogang Liu; Ying Ji; Suhong Mu; Hongchi Wu; Rujuan Xie
Journal:  Cent Eur J Immunol       Date:  2014-06-27       Impact factor: 2.085

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.